Study guide
12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies
ABIM Critical Care Medicine Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy
1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy
2 Chapter 2: Acute Respiratory Failure & ARDS
2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO
3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies
3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage
4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies
4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome
5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation
5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support
6 Chapter 6: Shock Syndromes & Hemodynamic Principles
6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets
7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support
7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication
8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy
8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI
9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies
9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis
10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders
10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency
11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias
11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing
12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies
12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes
13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies
13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm
14 Chapter 14: Sepsis & Systemic Infectious Diseases
14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU
15 Chapter 15: ICU-Acquired & Severe Focal Infections
15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections
16 Chapter 16: Focal, Special-Host & Systemic Infections
16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses
17 Chapter 17: Neurocritical Care & Coma
17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage
18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States
18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy
19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness
19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination
20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis
20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis
21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies
21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia
22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis
22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes
23 Chapter 23: Trauma, Burns & Perioperative Critical Care
23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients
24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care
24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy
25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care
25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia
26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation
26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics
27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders
27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity
28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings
28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia
29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound
29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound
12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies
Key Takeaways Explain This Topic AI
Acute aortic regurgitation (AR) produces sudden, catastrophic elevation of left ventricular end-diastolic pressure (LVEDP) in a non-compliant ventricle, leading to premature closure of the mitral valve in diastole, a short, soft diastolic murmur, and the complete absence of wide pulse pressure or classic peripheral eponym signs.
Intra-aortic balloon counterpulsation (IABP) is strictly contraindicated in acute aortic regurgitation because balloon inflation during diastole increases retrograde regurgitant volume into the left ventricle, causing catastrophic ventricular overdistension and death; beta-blockers must also be avoided as compensatory tachycardia is essential to maintain cardiac output.
Acute mitral regurgitation (MR) from chordal rupture or papillary muscle rupture (predominantly posteromedial due to single blood supply from the posterior descending artery) produces giant systolic 'v' waves on pulmonary wedge pressure tracings and flash pulmonary edema; unlike acute AR, acute MR is an established indication for IABP counterpulsation.
Left-sided mechanical prosthetic valve thrombosis should be rapidly evaluated with transesophageal echocardiography and cine-fluoroscopy; ACC/AHA 2020 accepts either low-dose slow-infusion fibrinolysis (for example, tPA 25 mg over 6 h in TROIA or 25 mg over 25 h in PROMETEE) or emergency surgery for symptomatic obstructive thrombosis, whereas ESC 2021 favors surgery when surgical risk is acceptable; large thrombi (>= 0.8 cm^2) or failed lysis favor surgery.
Prosthetic valve endocarditis (PVE) is classified as early (< 1 year, dominated by Staphylococcus epidermidis and S. aureus) or late (> 1 year, similar to native valve flora); urgent surgical reoperation is indicated for persistent heart failure, perivalvular extension (abscess, fistula, heart block), resistant organisms, persistent bacteremia, or large mobile vegetations.
Last updated: October 2026
Acute Aortic Regurgitation (AR): Etiology and Pathophysiology
Acute severe aortic regurgitation is a life-threatening cardiovascular emergency requiring immediate recognition, precise pharmacological stabilization, and rapid surgical consultation. While chronic aortic regurgitation allows the left ventricle months to years to develop eccentric hypertrophy and dilate to accommodate large regurgitant volumes without high intracavitary pressures, acute aortic regurgitation delivers a sudden massive diastolic volume into a normal-sized, non-compliant left ventricle.
Etiological Spectrum
The primary etiologies of acute aortic regurgitation in the intensive care unit include:
Acute Stanford Type A Aortic Dissection : Retrograde extension of an intimal tear into the aortic root disrupts the commissural attachments of the aortic valve cusps, causes leaflet prolapse, or induces annular dilation, resulting in acute, massive regurgitation.
Infective Endocarditis (IE) : Rapid vegetative destruction, cusp perforation, flail aortic leaflet, or perivalvular annular abscess extending through the fibrous skeleton.
Blunt Thoracic Trauma : High-energy deceleration injury causing sudden avulsion or tear of an aortic cusp.
Iatrogenic / Transcatheter Complications : Cusp injury or severe paravalvular regurgitation following transcatheter aortic valve replacement (TAVR), balloon aortic valvuloplasty, or transcatheter structural heart interventions.
The Hemodynamic Crisis of Acute Aortic Regurgitation
In acute AR, during ventricular diastole, blood flows retrogradely from the high-pressure aorta directly into the left ventricle alongside antegrade flow entering from the left atrium. Because the non-dilated left ventricle has steep diastolic compliance ( d P / d V dP/dV d P / d V ), left ventricular end-diastolic volume (LVEDV) increases only modestly, but left ventricular end-diastolic pressure (LVEDP) surges catastrophically , often reaching 30 to 50 mmHg 30\text{ to }50\text{ mmHg} 30 to 50 mmHg within a few cardiac cycles.
This extreme elevation in LVEDP produces two immediate pathophysiological consequences:
Severe Forward Hypoperfusion : Forward effective stroke volume ( S V forward = S V total − S V regurgitant SV_{\text{forward}} = SV_{\text{total}} - SV_{\text{regurgitant}} S V forward = S V total − S V regurgitant ) drops precipitously, producing cardiogenic shock, profound lactic acidosis, and organ hypoperfusion.
Acute Hydrostatic Pulmonary Edema : When LVEDP exceeds left atrial pressure, backward transmission of pressure triggers extreme pulmonary venous hypertension and severe flash pulmonary edema.
Premature Mitral Valve Closure and Auscultatory Hallmarks
The pathognomonic physical and echocardiographic finding in acute severe AR is premature diastolic closure of the mitral valve . Because LVEDP rises so rapidly in mid-to-late diastole, it quickly exceeds left atrial pressure before electrical ventricular systole begins. The pressure gradient across the mitral valve reverses in diastole, forcing the mitral leaflets closed prior to the onset of the QRS complex on the electrocardiogram:
On M-mode echocardiography , premature coaptation of the anterior and posterior mitral valve leaflets in mid-diastole (well before the QRS) is a direct marker of life-threateningly elevated LVEDP.
On auscultation, the first heart sound ( S 1 S_1 S 1 ) is markedly soft or completely absent because the mitral valve has already snapped shut in diastole and cannot close with normal systolic velocity.
The Diastolic Murmur : Unlike the loud, blowing, holodiastolic decrescendo murmur of chronic AR, the murmur of acute AR is short, soft, low-pitched, and early diastolic . As LVEDP surges to meet aortic diastolic pressure, the diastolic pressure gradient between the aorta and left ventricle rapidly equilibrates to near zero in mid-diastole, causing regurgitant flow to cease well before systole.
Absence of Chronic Peripheral Signs
In chronic AR, a large total stroke volume ejected into a dilated, compliant arterial tree produces a wide pulse pressure (e.g., 160 / 40 mmHg 160/40\text{ mmHg} 160/40 mmHg ) and famous peripheral eponyms (water-hammer Corrigan's pulse, Quincke's capillary pulsations, Duroziez's sign, Hill's sign). In acute AR, forward stroke volume is severely curtailed, peripheral vasoconstriction is intense, and aortic diastolic pressure rapidly equilibrates with elevated LVEDP. Consequently:
The pulse pressure is normal or narrow (e.g., 95 / 70 mmHg 95/70\text{ mmHg} 95/70 mmHg ).
All classic peripheral eponyms of chronic AR are strictly ABSENT .
Hemodynamic Management and Absolute Contraindications in Acute AR
Recognizing acute aortic regurgitation requires adhering to strict pharmacological and mechanical rules while mobilizing cardiac surgery:
The Lethal Hazard of Intra-Aortic Balloon Counterpulsation (IABP)
Caution
Intra-aortic balloon counterpulsation (IABP) is STRICTLY CONTRAINDICATED in aortic regurgitation. Normal IABP function inflates the balloon during diastole to augment aortic root diastolic pressure and enhance coronary perfusion. In the presence of an incompetent aortic valve, diastolic balloon inflation forces augmented diastolic blood backwards directly across the aortic valve into the left ventricle. This causes catastrophic left ventricular overdistension, acute pulmonary hemorrhage, acute papillary muscle ischemia, electromechanical dissociation, and rapid death.
Avoidance of Beta-Blockers
In acute AR, effective forward stroke volume is critically restricted. To preserve cardiac output ( C O = H R × S V CO = HR \times SV CO = H R × S V ), the patient's autonomic nervous system generates a robust, compensatory sinus tachycardia. A higher heart rate shortens the duration of diastole, which directly limits the time available for regurgitant volume to flow back into the left ventricle per beat.
Administering beta-blockers (e.g., metoprolol, esmolol, labetalol) eliminates this vital compensatory tachycardia. Prolonging diastole allows a massive increase in regurgitant volume per cardiac cycle, driving LVEDP even higher and precipitating immediate asystole or pulseless electrical activity (PEA).
Medical Stabilization and Urgent Surgical Timing
Medical management serves purely as a brief bridge to the operating room:
Vasodilators : Intravenous sodium nitroprusside reduces systemic vascular resistance, promoting forward stroke volume and reducing the regurgitant fraction. It is safe only if systemic arterial pressure can be maintained (SBP > 90-100 mmHg).
Inotropes : Intravenous dobutamine or dopamine augments forward contractility and provides mild chronotropic and vasodilatory properties to maintain forward cardiac output.
Vasopressors : If profound shock is present, norepinephrine can maintain perfusion pressure, but excessive vasoconstriction increases afterload and worsens regurgitant fraction; it should be titrated cautiously.
Definitive Surgery : Emergent open surgical aortic valve replacement (AVR) or root replacement is the only definitive therapy and must not be delayed.
Acute Mitral Regurgitation (MR): Mechanics and Management
Acute severe mitral regurgitation results from an abrupt structural disruption of the mitral valve apparatus, which consists of the leaflets, annulus, chordae tendineae, and papillary muscles.
Mechanisms and Vascular Anatomy of Papillary Muscle Rupture
Acute MR in the ICU commonly arises from:
Acute Myocardial Infarction with Papillary Muscle Rupture : Occurs typically 2 to 7 days 2\text{ to }7\text{ days} 2 to 7 days following acute myocardial infarction. The posteromedial papillary muscle ruptures 6 to 10 times more frequently than the anterolateral papillary muscle:
Posteromedial Papillary Muscle : Has a single, solitary blood supply provided entirely by the posterior descending artery (PDA; branching from the right coronary artery [RCA] in 85 % 85\% 85% of patients, or the left circumflex [LCx] in 15 % 15\% 15% ). Ischemia or occlusion of the PDA results in transmural infarction and catastrophic rupture.
Anterolateral Papillary Muscle : Possesses a dual blood supply from both the left anterior descending (LAD) diagonal branches and the LCx obtuse marginal branches, rendering it significantly more resistant to complete ischemic necrosis.
Infective Endocarditis : Destruction of the mitral leaflets, perforation, or chordal rupture secondary to active infection.
Degenerative / Spontaneous Chordal Rupture : Sudden rupture of primary chordae in patients with underlying myxomatous valve disease (mitral valve prolapse).
Blunt Chest Trauma : Rupture of chordae or papillary muscles from sudden compressive deceleration.
Pathophysiology and Giant "v" Waves
In acute MR, a large regurgitant volume is suddenly ejected during ventricular systole backwards into a normal-sized, non-compliant left atrium. The left atrial volume-pressure curve is steep:
Acute systolic volume overload creates a towering systolic pressure peak in the left atrium, reflected on pulmonary artery wedge pressure (PAWP) tracings as giant regurgitant "v" waves (often peaking at 40 to 70 mmHg 40\text{ to }70\text{ mmHg} 40 to 70 mmHg ).
These giant "v" waves are transmitted backward directly into the pulmonary venous and capillary beds, causing rapid, severe hydrostatic pulmonary edema.
On auscultation, the murmur of acute MR is often deceptive: it is frequently early systolic, soft, decrescendo, and terminates before S 2 S_2 S 2 . This occurs because late in systole, the pressure in the stiff, non-compliant left atrium rapidly approaches left ventricular systolic pressure, eliminating the pressure gradient driving regurgitation.
Medical and Mechanical Circulatory Support
Unlike acute aortic regurgitation, acute mitral regurgitation responds exceptionally well to mechanical circulatory support:
Intra-Aortic Balloon Counterpulsation (IABP) IS INDICATED : In acute MR, the IABP is a premier bridging modality. Rapid balloon deflation immediately prior to ventricular systole creates an afterload vacuum in the ascending aorta, markedly lowering LV afterload. This dramatically favors forward flow into the aorta, slashes the regurgitant fraction flowing backward into the left atrium, shrinks the giant "v" waves, and resolves pulmonary edema. Diastolic balloon inflation also improves coronary perfusion to the ischemic myocardium.
Vasodilators : Intravenous sodium nitroprusside is the preferred pharmacologic agent, reducing afterload and increasing forward cardiac output.
Definitive Surgery : Emergent surgical mitral valve repair or replacement is mandatory.
Feature Acute Aortic Regurgitation (AR) Acute Mitral Regurgitation (MR)
Primary Etiologies Type A dissection, infective endocarditis, blunt trauma Papillary muscle rupture (post-MI), chordal rupture, endocarditis
Left Ventricular Geometry Normal size, acutely non-compliant Normal size, hyperdynamic initially
Auscultatory Murmur Short, soft, early diastolic decrescendo; soft/absent S 1 S_1 S 1 Short, soft, early systolic decrescendo; loud S 4 S_4 S 4
Pulse Pressure Normal or narrow (due to low forward SV) Normal or narrow
Pathognomonic Finding Premature diastolic mitral valve closure on echo Giant systolic "v" waves on PAWP tracing
IABP Counterpulsation STRICTLY CONTRAINDICATED (causes lethal LV distension) STRONGLY INDICATED (reduces afterload and regurgitant volume)
Beta-Blocker Administration AVOID (compensatory tachycardia is required) Avoid if in cardiogenic shock; cautiously permitted if hypertensive
- Medical Bridge IV nitroprusside ± \pm ± dobutamine IV nitroprusside + IABP / Impella
- Definitive Treatment Emergent surgical valve/root replacement Emergent surgical valve repair or replacement
- Prosthetic Valve Emergencies: Thrombosis, Endocarditis & Paravalvular Leaks
Patients with prosthetic heart valves (mechanical or bioprosthetic) who present to the ICU with acute dyspnea, shock, or systemic embolization must be evaluated for three life-threatening complications.
Mechanical and Bioprosthetic Valve Thrombosis
Prosthetic valve thrombosis (PVT) is most frequent with mechanical valves (annual incidence 0.3 % to 1.3 % 0.3\%\text{ to }1.3\% 0.3% to 1.3% in left-sided valves, up to 8 % 8\% 8% in tricuspid valves), especially in the setting of subtherapeutic anticoagulation (international normalized ratio [INR] < 2.0 − 2.5 < 2.0-2.5 < 2.0 − 2.5 ).
Clinical Presentation : Acute pulmonary edema, cardiogenic shock, muffled or absent prosthetic closing clicks, new regurgitant or obstructive murmur, or systemic thromboembolic stroke.
Multimodal Diagnostic Evaluation :
Transthoracic Echocardiography (TTE) : First-line imaging to detect elevated peak and mean transvalvular gradients, decreased effective orifice area (EOA), and right/left ventricular dysfunction.
Transesophageal Echocardiography (TEE) : Essential for left-sided prosthetic valves. Overcomes acoustic shadowing from mechanical rings to visualize thrombus size, location (atrial vs. ventricular aspect), mobility, and extension.
Cine-Fluoroscopy : The gold standard modality for assessing mechanical disc or leaflet motion. It provides real-time radiographic visualization of leaflet opening and closing angles, readily identifying restricted or immobile tilting discs that ultrasound may miss.
Management of Left-Sided Mechanical Valve Thrombosis
Management is dictated by thrombus size, functional class, and surgical risk:
Emergent Surgery (Valve Replacement or Thrombectomy) : Indicated for patients with:
Obstructive thrombosis with cardiogenic shock (NYHA Class IV).
Large thrombus burden (thrombus area ≥ 0.8 cm 2 \ge 0.8\text{ cm}^2 ≥ 0.8 cm 2 or mobile length ≥ 10 mm \ge 10\text{ mm} ≥ 10 mm on TEE), due to excessive risk of cerebral embolization with thrombolysis ( > 15 % > 15\% > 15% ).
Absolute contraindications to fibrinolytic therapy.
Failed fibrinolysis.
Low-Dose, Slow-Infusion Fibrinolysis Protocol :
Historical rapid high-dose protocols (e.g., streptokinase or tPA 100 mg 100\text{ mg} 100 mg over 2 hours) carried unacceptable rates of major bleeding ( > 10 % > 10\% > 10% ) and fatal intracranial hemorrhage.
Modern Protocols (Özkan and colleagues) : The TROIA registry used low-dose tPA 25 mg 25\text{ mg} 25 mg over 6 hours without a bolus, and the PROMETEE study used an ultraslow 25 mg 25\text{ mg} 25 mg infusion over 25 hours without a bolus; in both, the dose was repeated after TEE reassessment until the thrombus resolved (PROMETEE allowed up to eight sessions), with unfractionated heparin between sessions. Success rates were about 90% with low rates of major complications, and the ultraslow regimen had the fewest.
Guideline Positions : The 2020 ACC/AHA guideline recommends urgent treatment with either slow-infusion low-dose fibrinolysis or emergency surgery for symptomatic obstructive left-sided mechanical valve thrombosis, choosing by thrombus size, surgical risk, and local expertise. The 2021 ESC/EACTS guideline favors urgent surgery for obstructive left-sided thrombosis in patients without serious comorbidity and reserves fibrinolysis for patients at high surgical risk, when surgery is unavailable, or for right-sided prosthetic thrombosis.
Not to Confuse: PROACT is the On-X mechanical valve anticoagulation trial (lower INR targets), not a fibrinolysis regimen.
Prosthetic Valve Endocarditis (PVE)
PVE accounts for 20 % to 30 % 20\%\text{ to }30\% 20% to 30% of all infective endocarditis cases and carries a hospital mortality of 30 % to 50 % 30\%\text{ to }50\% 30% to 50% :
Early PVE ( < 1 year < 1\text{ year} < 1 year post-surgery) : Primarily acquired perioperatively in the hospital. The dominant pathogen is methicillin-resistant Staphylococcus epidermidis (MRSE) , followed by Staphylococcus aureus , Gram-negative bacilli, and fungi ( Candida ). MRSE forms an impenetrable biofilm on foreign material, frequently invading the sewing ring and perivalvular annular tissue to produce ring abscesses, pseudoaneurysms, and valve dehiscence.
Late PVE ( > 1 year > 1\text{ year} > 1 year post-surgery) : Acquired in the community. Microbiology mirrors native valve endocarditis: viridans group streptococci, Enterococcus faecalis , and community-acquired S. aureus .
Indications for Urgent Surgical Intervention in PVE :
Severe heart failure or cardiogenic shock refractory to medical therapy.
Perivalvular extension: annular abscess, pericardial fistula, new atrioventricular block, or pseudoaneurysm.
Persistent bacteremia or positive blood cultures ≥ 5 − 7 days \ge 5-7\text{ days} ≥ 5 − 7 days despite targeted antimicrobial therapy.
Infection caused by multidrug-resistant pathogens or fungi ( Candida , Aspergillus ).
Large mobile vegetations ( > 10 mm > 10\text{ mm} > 10 mm ) associated with embolic events.
Significant prosthetic valve dehiscence or severe paravalvular regurgitation.
Paravalvular Leak (PVL)
Paravalvular leaks occur when tissue retraction, suture rupture, annular calcification, or endocarditis creates a channel between the prosthetic sewing ring and surrounding cardiac tissue:
Clinical Manifestations : Heart failure from volume overload, and/or severe Coombs-negative mechanical hemolytic anemia caused by high-velocity shear stress tearing erythrocytes across the narrow defect. Diagnostic labs show elevated serum lactate dehydrogenase ( > 1 , 000 U/L > 1,000\text{ U/L} > 1 , 000 U/L ), undetectable haptoglobin, reticulocytosis, and peripheral blood smear showing numerous schistocytes.
Management : 3D transesophageal echocardiography precisely maps the defect. Surgical re-anchoring or valve re-replacement is indicated for large leaks or active infection. In patients with prohibitive surgical risk, percutaneous transcatheter closure using dedicated vascular plug occluders (e.g., Amplatzer plugs) is the preferred alternative.
Severe Aortic Stenosis in the Critically Ill Patient
A stenotic aortic valve creates a fixed outflow obstruction . The hypertrophied left ventricle depends on preload, sinus rhythm (atrial kick), and diastolic coronary perfusion pressure.
Severity markers (echocardiography) : peak velocity at least 4 m/s 4\text{ m/s} 4 m/s , mean gradient at least 40 mmHg 40\text{ mmHg} 40 mmHg , or valve area at most 1.0 cm 2 1.0\text{ cm}^2 1.0 cm 2 . A low-flow, low-gradient pattern (area at most 1.0 cm 2 1.0\text{ cm}^2 1.0 cm 2 with a mean gradient below 40 mmHg 40\text{ mmHg} 40 mmHg and reduced ejection fraction) needs dobutamine stress echocardiography or a CT calcium score to separate true severe stenosis from pseudostenosis.
Hypotension is poorly tolerated : falling diastolic pressure cuts coronary flow to a thick ventricle, which worsens ischemia and output (a spiral). Treat hypotension early with an alpha-agonist (phenylephrine or norepinephrine).
Avoid : large preload reduction (aggressive diuresis, nitrates, high-dose sedatives that cause venodilation), sudden afterload reduction, and tachycardia. Restore sinus rhythm promptly; new atrial fibrillation with hypotension needs cardioversion.
Decompensated aortic stenosis with low output : inotropes are a short bridge. In older single-center data, carefully titrated nitroprusside guided by a pulmonary artery catheter improved output in selected patients with severe left ventricular dysfunction and high systemic resistance. Definitive relief , with urgent transcatheter aortic valve replacement (TAVR) or balloon aortic valvuloplasty as a bridge, is the goal.
Procedures and sedation : induction and positive-pressure ventilation can precipitate collapse. Prepare vasopressors before intubation and choose hemodynamically neutral agents.
Mitral Stenosis
Pressure in the left atrium is set by flow across the valve and diastolic filling time . Tachycardia shortens diastole, raises left atrial pressure, and causes pulmonary edema, which is why decompensation often follows new atrial fibrillation, fever, anemia, sepsis, or pregnancy .
Management : rate control (beta-blocker or nondihydropyridine calcium-channel blocker) to lengthen diastole, diuretics for congestion, and cardioversion for unstable atrial fibrillation. Patients with rheumatic mitral stenosis and atrial fibrillation need warfarin (DOACs are not recommended in moderate-to-severe rheumatic mitral stenosis). Percutaneous balloon mitral commissurotomy, when the valve is suitable, or surgery is definitive.
Tricuspid and Right-Sided Valve Emergencies
Tricuspid valve endocarditis (commonly Staphylococcus aureus in people who inject drugs, or device-related) presents with fever, bacteremia, and septic pulmonary emboli (multiple peripheral cavitating nodules).
Severe tricuspid regurgitation causes venous congestion, hepatic congestion, and a pulsatile liver. It frequently reflects right ventricular dilation from pulmonary hypertension or pacemaker leads.
Surgery for right-sided endocarditis is considered for persistent bacteremia despite appropriate therapy, very large vegetations with recurrent emboli, or right heart failure that does not respond to medical therapy.